These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29874282)

  • 1. A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention.
    Zewde N; Morikis D
    PLoS One; 2018; 13(6):e0198644. PubMed ID: 29874282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
    J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options.
    Sanghera P; Ghanta M; Ozay F; Ariyamuthu VK; Tanriover B
    Am J Med Sci; 2017 Dec; 354(6):533-538. PubMed ID: 29208248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
    Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
    Front Immunol; 2021; 12():690821. PubMed ID: 34177949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
    Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-complement therapy for glomerular diseases.
    Bomback AS
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
    Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
    Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
    Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
    Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes.
    Reynolds R; Hartnett ME; Atkinson JP; Giclas PC; Rosner B; Seddon JM
    Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5818-27. PubMed ID: 19661236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease.
    Caruso A; Vollmer J; Machacek M; Kortvely E
    PLoS Comput Biol; 2020 Oct; 16(10):e1008139. PubMed ID: 33006965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs.
    de Cordoba SR; Tortajada A; Harris CL; Morgan BP
    Immunobiology; 2012 Nov; 217(11):1034-46. PubMed ID: 22964229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative complement pathway assessment in patients with atypical HUS.
    Roumenina LT; Loirat C; Dragon-Durey MA; Halbwachs-Mecarelli L; Sautes-Fridman C; Fremeaux-Bacchi V
    J Immunol Methods; 2011 Feb; 365(1-2):8-26. PubMed ID: 21215749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of complement in AMD.
    Zipfel PF; Lauer N; Skerka C
    Adv Exp Med Biol; 2010; 703():9-24. PubMed ID: 20711704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities for new therapies based on the natural regulators of complement activation.
    Brook E; Herbert AP; Jenkins HT; Soares DC; Barlow PN
    Ann N Y Acad Sci; 2005 Nov; 1056():176-88. PubMed ID: 16387686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19: A collision of complement, coagulation and inflammatory pathways.
    Chauhan AJ; Wiffen LJ; Brown TP
    J Thromb Haemost; 2020 Sep; 18(9):2110-2117. PubMed ID: 32608159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecules Great and Small: The Complement System.
    Mathern DR; Heeger PS
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1636-50. PubMed ID: 25568220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.
    Richards A; Kavanagh D; Atkinson JP
    Adv Immunol; 2007; 96():141-77. PubMed ID: 17981206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.